Booz Allen Hamilton arrives at the final session of June with a month-long slide that has carried the stock down 23% to $60.67 — and the Street is still cutting targets rather than defending the name.
The most important development this week came from the analyst community. Citigroup's John Godyn lowered his price target to $69 from $88 on July 1, maintaining a Neutral rating — the second time he has cut the target since April, when it fell from $109 to $87. The direction of travel across the Street is uniformly lower: JP Morgan trimmed to $85, Truist cut to $85, and Wells Fargo initiated at $85 Equal-Weight in April. Against a consensus mean target of roughly $92, the stock at $60.67 implies theoretical upside of more than 50%, but that gap reflects how far the stock has fallen rather than genuine bullish conviction — the target distribution has been compressing downward for months, and no major firm has raised its target since January. Stifel did upgrade to Buy in late May, setting a $110 target, but that now looks like an outlier rather than a turning point.
Valuation has been repriced sharply. The price-to-earnings multiple has compressed by roughly 2.6 points over the past 30 days, now running at about 9.6x trailing earnings, while EV/EBITDA has slipped to 8.5x. Factor scores add nuance: the company earns a strong 84th-percentile rank on EPS surprise, meaning it has consistently beaten estimates, but forward earnings momentum is weak — the 12-month forward EPS growth rank sits at just 25. The dividend score is a perfect 100, though the dividend history in the data runs only to 2022 and the yield component deserves verification against current filings. On balance, the stock looks cheap on backward-looking multiples but lacks a near-term catalyst to close the gap to targets.
Positioning in the lending market does not reinforce the bearish thesis. Availability is extraordinarily loose — currently at roughly 5,300%, meaning there are vastly more shares available to borrow than are currently shorted. That is well above the 52-week low of around 685%, and the trend has been toward even more availability over the past two weeks. Cost to borrow, while up 22% on the week, remains negligible at 0.49% — firmly in the "easy borrow" category. Short interest itself is moderate at 6.4% of free float, up about 4% on the week but barely changed over the month. The ORTEX short score has edged up to 43.5 from 42.1 two weeks ago, but that remains squarely mid-range, ranking in just the 30th percentile against the broader universe. There is no meaningful short squeeze dynamic here.
Options tell a similar story of mild caution rather than outright fear. The put/call ratio at 1.24 is actually slightly below its 20-day average of 1.28, a modest half-standard-deviation move to the downside — options traders have been defensive on BAH for months, but they are not adding to that defensiveness this week. The PCR has drifted lower from readings above 1.4 in mid-May, suggesting hedging demand has cooled even as the share price has fallen. Peer performance adds more texture: SAIC fell nearly as sharply as BAH on the day (down 2.3%) while Gartner and Leidos gained around 2.5% — the sector is not moving as a uniform bloc, and BAH is underperforming the recoveries seen elsewhere in government services.
The next fixed point on the calendar is the Q1 fiscal 2027 earnings report on July 22. The most recent comparable print, on May 22, delivered a 4.7% one-day gain and a 3.7% five-day gain — a reminder that BAH can move sharply higher on a beat. Whether the current analyst target compression reflects a genuine reassessment of contract visibility, or simply follows the price lower, is what the July 22 print will begin to answer.
See the live data behind this article on ORTEX.
Open BAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
